Denali Therapeutics Inc. financial data

Symbol
DNLI on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 968% % -7.7%
Debt-to-equity 13% % 39%
Return On Equity -50% % -60%
Return On Assets -44% % -55%
Operating Margin -66% % 83%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 158,591,491 shares 9.2%
Common Stock, Shares, Outstanding 156,182,177 shares 8.3%
Entity Public Float $1,100,000,000 USD -42%
Weighted Average Number of Shares Outstanding, Basic 172,649,097 shares 5%
Weighted Average Number of Shares Outstanding, Diluted 172,649,097 shares 5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $295,390,000 USD 191%
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD -100%
Research and Development Expense $418,778,000 USD 5.6%
General and Administrative Expense $136,564,000 USD 30%
Operating Income (Loss) $555,342,000 USD -14%
Net Income (Loss) Attributable to Parent $512,540,000 USD -21%
Earnings Per Share, Basic -2.97 USD/shares -16%
Earnings Per Share, Diluted -2.97 USD/shares -16%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $205,326,000 USD 17%
Marketable Securities, Current $662,553,000 USD 0.79%
Assets, Current $900,658,000 USD 4.2%
Property, Plant and Equipment, Net $52,402,000 USD -5.1%
Operating Lease, Right-of-Use Asset $19,002,000 USD -17%
Other Assets, Noncurrent $25,939,000 USD 4.8%
Assets $1,144,854,000 USD -17%
Accounts Payable, Current $3,330,000 USD -70%
Employee-related Liabilities, Current $32,179,000 USD 30%
Accrued Liabilities, Current $95,021,000 USD 4.3%
Liabilities, Current $98,351,000 USD -3.8%
Operating Lease, Liability, Noncurrent $27,210,000 USD -26%
Liabilities $131,093,000 USD -9.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax $682,000 USD -66%
Retained Earnings (Accumulated Deficit) $2,051,524,000 USD -33%
Stockholders' Equity Attributable to Parent $1,013,761,000 USD -18%
Liabilities and Equity $1,144,854,000 USD -17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $131,468,000 USD -16%
Net Cash Provided by (Used in) Financing Activities $3,762,000 USD -101%
Net Cash Provided by (Used in) Investing Activities $18,748,000 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 156,182,177 shares 8.3%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $116,482,000 USD -75%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $208,432,000 USD 18%
Deferred Tax Assets, Valuation Allowance $630,806,000 USD 29%
Deferred Tax Assets, Gross $646,486,000 USD 28%
Operating Lease, Liability $36,673,000 USD -18%
Payments to Acquire Property, Plant, and Equipment $5,078,000 USD 136%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $513,878,000 USD -22%
Lessee, Operating Lease, Liability, to be Paid $42,148,000 USD -22%
Property, Plant and Equipment, Gross $115,297,000 USD 7.5%
Operating Lease, Liability, Current $9,463,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year Two $12,584,000 USD 3.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $12,182,000 USD 3.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $5,475,000 USD -39%
Lessee, Operating Lease, Liability, to be Paid, Year Three $13,001,000 USD 3.3%
Deferred Tax Assets, Operating Loss Carryforwards $229,535,000 USD 102%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40,000,000 shares 0%
Unrecognized Tax Benefits $39,252,000 USD 16%
Lessee, Operating Lease, Liability, to be Paid, Year Four $4,381,000 USD -66%
Operating Lease, Payments $11,793,000 USD 3.3%
Additional Paid in Capital $3,062,715,000 USD 11%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $2,325,000 USD 7.5%
Deferred Tax Assets, Net of Valuation Allowance $15,681,000 USD -4.1%
Share-based Payment Arrangement, Expense $99,633,000 USD -3.2%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%